{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:03:26Z","timestamp":1787853806484,"version":"build-2784847793"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmc.2024.117932","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T18:53:51Z","timestamp":1727722431000},"page":"117932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design of a potent and selective dual JAK1\/TYK2 inhibitor"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1521-9254","authenticated-orcid":false,"given":"Oscar","family":"Mammoliti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Menet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-3154","authenticated-orcid":false,"given":"C\u00e9line","family":"Cottereaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"De Blieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghjuvanni","family":"Coti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2666-8589","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Geney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-3282","authenticated-orcid":false,"given":"Line","family":"Oste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3130-0826","authenticated-orcid":false,"given":"Koen","family":"Ostyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-9565","authenticated-orcid":false,"given":"Adeline","family":"Palisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Quinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-3226","authenticated-orcid":false,"given":"Monica","family":"Borgonovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6277-1711","authenticated-orcid":false,"given":"Catherine","family":"Jagerschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"De Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5316-3482","authenticated-orcid":false,"given":"B\u00e9atrice","family":"Vayssiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-7347","authenticated-orcid":false,"given":"Miriam","family":"L\u00f3pez-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Brys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Amantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-9263","authenticated-orcid":false,"given":"Ren\u00e9","family":"Galien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-5439","authenticated-orcid":false,"given":"Caroline","family":"Joannesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117932_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117932_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis","volume":"21","author":"Nakase","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bmc.2024.117932_b0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2024.117932_b0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10787-021-00813-y","article-title":"Role of intracellular signaling pathways and their inhibitors in the treatment of inflammation","volume":"29","author":"Nailwal","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bmc.2024.117932_b0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2024.117932_b0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.bmc.2024.117932_b0035","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117932_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/ph15010048","article-title":"Jakinibs of all trades: inhibiting cytokine signaling in immune-mediated pathologies","volume":"15","author":"Alexander","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmc.2024.117932_b0045","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0050","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0055","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2024.117932_b0060","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.bmc.2024.117932_b0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bmc.2024.117932_b0075","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bmc.2024.117932_b0080","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2024.117932_b0085","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bmc.2024.117932_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmc.2024.117932_b0095","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.bmc.2024.117932_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00044","article-title":"The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets","volume":"10","author":"Gorman","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0105","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0110","unstructured":"Stelara. European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara (accessed 2024-05-03)."},{"key":"10.1016\/j.bmc.2024.117932_b0115","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2024.117932_b0120","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1177\/0961203316638933","article-title":"Association between TYK2 polymorphisms and susceptibility to autoimmune rheumatic diseases: a meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.bmc.2024.117932_b0125","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1038\/s41598-018-25282-2","article-title":"The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells","volume":"8","author":"Enerb\u00e4ck","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2024.117932_b0130","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41588-018-0216-7","article-title":"Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes","volume":"50","author":"Westra","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.bmc.2024.117932_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48451-3","article-title":"Catalytically impaired TYK2 variants are protective against childhood- and adult-onset systemic lupus erythematosus in Mexicans","volume":"9","author":"Contreras-Cubas","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2024.117932_b0140","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2020-0425","article-title":"Association of TYK2 polymorphisms with autoimmune diseases: a comprehensive and updated systematic review with meta-analysis","volume":"44","author":"Pellenz","year":"2021","journal-title":"Genet Mol Biol"},{"key":"10.1016\/j.bmc.2024.117932_b0145","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2665-9913(20)30397-0","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study","volume":"3","author":"Tehlirian","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.bmc.2024.117932_b0150","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2024.117932_b0160","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.1021\/acs.jmedchem.8b01397","article-title":"A dual inhibition, a better solution: development of a JAK1\/TYK2 inhibitor","volume":"61","author":"Menet","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117932_b0165","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.4049\/jimmunol.0902740","article-title":"Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis","volume":"183","author":"Oyamada","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ecco-jcc\/jjaa199","article-title":"Tyrosine kinase 2 signalling drives pathogenic T cells in colitis","volume":"15","author":"De Vries","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bmc.2024.117932_b0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2024.117932_b0185","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117932_b0190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13555-021-00649-y","article-title":"Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial","volume":"12","author":"Tha\u00e7i","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.bmc.2024.117932_b0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bmc.2024.117932_b0200","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bmc.2024.117932_b0205","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bmc.2024.117932_b0210","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bmc.2024.117932_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100156","article-title":"Safety and efficacy of ritlecitinib and brepocitinib in alopecia areata: results from the crossover open-label extension of the allegro phase 2a trial","volume":"2","author":"King","year":"2022","journal-title":"JID Innov."},{"key":"10.1016\/j.bmc.2024.117932_b0220","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1016\/j.bmcl.2013.08.030","article-title":"The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations","volume":"23","author":"Shultz","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117932_b0225","unstructured":"Determination of the co-crystal structure of the JAK1 JH1 domain with compound 10 was conducted by Proteros Biostructures GmbH (Martinsried, Germany)."},{"key":"10.1016\/j.bmc.2024.117932_b0230","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1021\/ja0771033","article-title":"Role of the active-site solvent in the thermodynamics of factor Xa ligand binding","volume":"130","author":"Abel","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117932_b0235","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1073\/pnas.0610202104","article-title":"Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding","volume":"104","author":"Young","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117932_b0240","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1107\/S0108768196005319","article-title":"The hydrogen-bond C-H donor and \u03c0-acceptor characteristics of three-membered rings","volume":"52","author":"Allen","year":"1996","journal-title":"Acta Crystallogr Sect B"},{"key":"10.1016\/j.bmc.2024.117932_b0245","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1021\/jm400266t","article-title":"Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors","volume":"56","author":"Liang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117932_b0250","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.4049\/jimmunol.170.11.5438","article-title":"IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14\/p40 transgenic mice: evidence for enhanced cutaneous immunity","volume":"170","author":"Kopp","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2024.117932_b0255","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmc.2024.117932_b0260","unstructured":"Menet CJM, Schmitt BA, Geney RJJ, et al. Imidazo [4,5-c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases. Patent no. WO2013117645; 2013."},{"key":"10.1016\/j.bmc.2024.117932_b0265","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","article-title":"Epik: a software program for pKa prediction and protonation state generation for drug-like molecules","volume":"21","author":"Shelley","year":"2007","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmc.2024.117932_b0270","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","article-title":"Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution","volume":"24","author":"Greenwood","year":"2010","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmc.2024.117932_b0275","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2024.117932_b0280","doi-asserted-by":"crossref","unstructured":"Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Fantino E. Crystal structures of JAK1 and JAK2 inhibitor complexes. RCSB Protein Data Bank; 2009. pdb.org\/pdb?id=pdb_00003eyg (accessed 2024-05-03).","DOI":"10.2210\/pdb3eyh\/pdb"},{"key":"10.1016\/j.bmc.2024.117932_b0285","doi-asserted-by":"crossref","unstructured":"Lupardus PJ, Steffek M. The Jak1 kinase domain in complex with inhibitor. Worldwide Protein Databank; 2012. pdb.org\/pdb?id=pdb_00004ehz (accessed 2024-05-03).","DOI":"10.2210\/pdb4ehz\/pdb"},{"key":"10.1016\/j.bmc.2024.117932_b0290","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1021\/jm300628c","article-title":"Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2","volume":"55","author":"Zak","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117932_b0295","unstructured":"RCSB Protein Data Bank. https:\/\/www.rcsb.org\/(accessed 2024-05-03)."},{"key":"10.1016\/j.bmc.2024.117932_b0300","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2024.117932_b0305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Madhavi Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmc.2024.117932_b0310","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.bmc.2024.117932_b0315","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117932_b0320","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117932_b0325","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117932_b0330","series-title":"SC \u201906: proceedings of the 2006 ACM\/IEEE conference on supercomputing, Tampa, FL, USA","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters","author":"Bowers","year":"2006"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T12:34:29Z","timestamp":1730378069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624003468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":66,"alternative-id":["S0968089624003468"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117932","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of a potent and selective dual JAK1\/TYK2 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Galapagos NV. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117932"}}